$KYNB

Oppenheimer maintained an Outperform rating and $35.00 price target for Kyntra Bio (NASDAQ:KYNB) after the company restructured its royalty financing agreement, reducing obligations to $65M from $125M. The company made a $42.6M payment, eliminating $60M in future obligations while retaining royalty economics. Kyntra Bio has a current ratio of 2.69 and is trading at $7.78, below analyst targets. Oppenheimer expects Phase 3 and Phase 2 data in 2026 and sees improved financial flexibility.

KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation • Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million • Company accelerated payment of $42.6 mi

Kyntra Bio (KYNB) reported Q2 2026 earnings with revenue of -$1.5M, net income of $12.0M, and $95.7M in cash. Clinical updates include FG-3246 Phase II enrollment and roxadustat Phase III plans. Management expects cash to last into 2028 and discussed potential partnerships for roxadustat.

Kyntra Bio (KYNB) reported Q2 2026 revenue of -$1.5M, a net income of $12.0M, and $95.7M in cash. Clinical trials for FG-3246 in prostate cancer and roxadustat in MDS showed progress. Operating expenses rose to $16.1M. Management expects cash to last into 2028 and is evaluating partnership options for roxadustat.

KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update • Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues

KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0000921299 false 0000921299 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12,

Kyntra Bio, Inc. (NASDAQ:KYNB) published its Q1 2026 earnings call presentation on May 11, 2026. This slide deck accompanies the company's first-quarter financial results. The article was written by SA Transcripts, a team dedicated to publishing earnings call materials.